Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:167
  • Home
  • Print this page
  • Email this page
Year : 2020  |  Volume : 5  |  Issue : 2  |  Page : 209-211

COVID-19 convalescent plasma product: Harvesting plasma from single unit whole blood, a cost effective alternative to plasmapheresis

Lok Samarpan Regional Blood Center, Surat, Gujarat, India

Correspondence Address:
Dr. Sanmukh R Joshi
Lok Samarpan Regional Blood Center, Surat, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/GJTM.GJTM_66_20

Rights and Permissions

The COVID-19 pandemic has affected people from almost all parts of the world. There is no specific pharmaceutical drug available. So also, there is no vaccine developed as yet. In the circumstance, the passive immunity imparted by the preformed antibody in the plasma from the convalescing patient could be a useful approach. COVID-19 convalescent plasma (CCP) can be collected by an automated apheresis device. However, the preparation becomes expensive, and average blood banks cannot afford to establish infrastructure in terms of machine and material requirements. The recommended dose of 200 mL of CCP for the treatment of a patient can easily be met from a single whole blood unit by any blood bank with the facility of blood component separation. This approach can significantly reduce the cost of the treatment to the patient with COVID-19.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded88    
    Comments [Add]    

Recommend this journal